136 related articles for article (PubMed ID: 22082470)
1. Petechial-like lesions, eye abnormalities, and albuminuria in a young boy.
Roganović J
Pediatr Dermatol; 2011; 28(6):727-728. PubMed ID: 22082470
[No Abstract] [Full Text] [Related]
2. Paradoxical Response to Enzyme Replacement Therapy of Fabry Disease Cardiomyopathy.
Frustaci A; Russo MA; Chimenti C
Circ Cardiovasc Imaging; 2016 Aug; 9(8):. PubMed ID: 27486136
[No Abstract] [Full Text] [Related]
3. Fabry disease previously diagnosed as Henoch-Schonlein purpura.
Kim JH; Han DH; Park MY; Choi SJ; Kim JK; Hwang SD; Jin SY
Korean J Intern Med; 2015 Nov; 30(6):925-7. PubMed ID: 26552470
[No Abstract] [Full Text] [Related]
4. Fabry disease in children: correlation between ocular manifestations, genotype and systemic clinical severity.
Allen LE; Cosgrave EM; Kersey JP; Ramaswami U
Br J Ophthalmol; 2010 Dec; 94(12):1602-5. PubMed ID: 20576773
[TBL] [Abstract][Full Text] [Related]
5. Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease.
Lenders M; Brand E
J Am Soc Nephrol; 2018 Sep; 29(9):2265-2278. PubMed ID: 30093456
[No Abstract] [Full Text] [Related]
6. Anderson-Fabry disease.
Di Toro A; Favalli V; Arbustini E
J Cardiovasc Med (Hagerstown); 2018 Feb; 19 Suppl 1():e1-e5. PubMed ID: 29538136
[No Abstract] [Full Text] [Related]
7. Fabry disease in an oligosymptomatic male.
Altarescu G; Elstein D
Isr Med Assoc J; 2011 Mar; 13(3):191-2. PubMed ID: 21608346
[No Abstract] [Full Text] [Related]
8. [Consensus for the study and treatment of Fabry disease. GETER Foundation].
García de Lorenzo A;
Med Clin (Barc); 2011 Jul; 137(4):178-83. PubMed ID: 21529855
[No Abstract] [Full Text] [Related]
9. Stroke and Chronic Kidney Disease in Fabry Disease.
Tapia D; Kimonis V
J Stroke Cerebrovasc Dis; 2021 Sep; 30(9):105423. PubMed ID: 33160817
[TBL] [Abstract][Full Text] [Related]
10. [Fabry disease from the neurologist's point of view: is it a rare cause of strokes?].
Marti-Martinez S; Climent V; Pampliega-Perez A; Martin-Estefania C; Leiva-Santana C
Rev Neurol; 2015 Jan; 60(2):93-5. PubMed ID: 25583594
[No Abstract] [Full Text] [Related]
11. An asymptomatic heterozygous female with fabry disease: implications for enzyme replacement therapy.
Inagaki S; Migita M; Hayakawa M; Fujita A; Yoshida J; Ishizaki M; Kotani M; Sakuraba H; Shimada T; Murakami M; Fukunaga Y
J Nippon Med Sch; 2005 Dec; 72(6):387-90. PubMed ID: 16415520
[TBL] [Abstract][Full Text] [Related]
12. [Enzyme replacement therapy in Fabry's disease].
Alvarez L; del Pozo C; Trigueros M; Sánchez L; Albero MD; López-Menchero R; Ortega E
Nefrologia; 2005; 25(3):322-7. PubMed ID: 16053014
[TBL] [Abstract][Full Text] [Related]
13. [Fabry disease].
Subran B; Montagner C; London J; Lidove O; Mauhin W
Rev Prat; 2020 May; 70(5):537-540. PubMed ID: 33058644
[TBL] [Abstract][Full Text] [Related]
14. Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage.
Wang RY; Abe JT; Cohen AH; Wilcox WR
J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S369-74. PubMed ID: 18937048
[TBL] [Abstract][Full Text] [Related]
15. Fabry disease and enzyme replacement therapy in classic patients with same mutation: different formulations--different outcome?
Politei J; Schenone AB; Cabrera G; Heguilen R; Szlago M
Clin Genet; 2016 Jan; 89(1):88-92. PubMed ID: 25817890
[TBL] [Abstract][Full Text] [Related]
16. Enzyme replacement therapy for Fabry disease: proving the clinical benefit.
Breunig F; Wanner C
Nephrol Dial Transplant; 2003 Jan; 18(1):7-9. PubMed ID: 12480950
[No Abstract] [Full Text] [Related]
17. [Third French multidisciplinary meeting on Fabry disease].
Germain DP
Rev Med Interne; 2010 Dec; 31 Suppl 2():S205-8. PubMed ID: 21211664
[No Abstract] [Full Text] [Related]
18. Identification of Fabry Disease in a Tertiary Referral Cohort of Patients with Hypertrophic Cardiomyopathy.
Maron MS; Xin W; Sims KB; Butler R; Haas TS; Rowin EJ; Desnick RJ; Maron BJ
Am J Med; 2018 Feb; 131(2):200.e1-200.e8. PubMed ID: 28943383
[TBL] [Abstract][Full Text] [Related]
19. [Multidisciplinary treatment in the long-term management of Fabry disease].
;
Zhonghua Nei Ke Za Zhi; 2023 Aug; 62(8):949-955. PubMed ID: 37528032
[TBL] [Abstract][Full Text] [Related]
20. A heterozygous female with Fabry disease due to a novel α-galactosidase A mutation exhibits a unique synaptopodin distribution in vacuolated podocytes.
Takahashi N; Yokoi S; Kasuno K; Kogami A; Tsukimura T; Togawa T; Saito S; Ohno K; Hara M; Kurosawa H; Hirayama Y; Kurose T; Yokoyama Y; Mikami D; Kimura H; Naiki H; Sakuraba H; Iwano M
Clin Nephrol; 2015 May; 83(5):301-8. PubMed ID: 25295576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
